Britta Smedegaard Andersen, Project Director, NEXT
“NEXT IS A DANISH PUBLIC-PRIVATE PARTNERSHIP WORKING TO STRENGTHEN DENMARK AS A PREFERRED COUNTRY FOR EARLY CLINICAL RESEARCH”
NEXT – National Experimental Therapy partnership – is a public-private partnership within clinical research which comprises all regions of Denmark and twelve pharmaceutical companies. The partnership was established on 1 November 2014 and has had an investment of DKK 92,4 million from the Danish Government (Innovation Fund Denmark (Innovationsfonden)) over a five-year period, and an investment from the partners of DKK 118 million.
NEXT will establish Denmark as a country of choice for the pharmaceutical industry for carrying out early clinical trials of new drugs in patients. In particular, NEXT focuses on proof of concept trials. NEXT is working to optimise all processes relating to the start-up and implementation of clinical trials, where optimising legal and statutory processes has a high priority. A high degree of predictability in the clinical trials is also a key element of NEXT. The trials start as planned, and the agreed number of patients are recruited.
The partnership’s current objective is to quadruple the sum of money that the pharmaceutical companies invest in early clinical trials in Denmark. This objective must be realised within five years, and it assumes that the Danish hospital departments are able to compete internationally with respect to quality, speed, proximity and precision. Excellent research and ground-breaking innovation are taking place at the NEXT centres under the joint headings ‘precision medicine’ or ‘personalised medicine’.
FORMER PROFESSIONAL POSITIONS:
Capital Region of Denmark: Senior Adviser within clinical development. Establishing a national One Stop Shop for the industry to the hospitals within clinical trials in Denmark.
ALK-Abelló: Head of Clinical Operations & International Clinical Trial Manager.
Novartis Healthcare A/S: Clinical Research Associate.